We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Comparative Study on the Effects of Incretin and Metformin on Lipid Profile and Oxidative Stress in Diabetic Rats.
- Authors
Shirali, Saeed; Hosseini, Seyed Ahmad; Yadollahpour, Ali; Babaali, Hasti; Babaali, Shouresh; Saki, Sara
- Abstract
Type 2 diabetes is a prevalent and growing problem worldwide. This study aimed to evaluate the effect of metformin and sitagliptin on lipid profile and oxidative stress in streptozotocin (STZ) induced diabetic albino Wistar rats. Twenty four neonatal rats (approximately 9±2 g), were randomly divided in to 4 groups: The control (n=6), untreated diabetic (n=6), diabetic treated by metformin (n=6) and treated by sitagliptin (n=6). The diabetes was induced in the subjects by intraperitoneal injecting of STZ with a dose of 90 mg/kg body weight. Then, the rats were kept 8 weeks under the same conditions then enrolled in the study. The group 3 and 4 was respectively gavaged by metformin (150 mg/kg/day) and sitagliptin (100 mg/kg/day) for one month. At the end, blood samples were collected from each rat. Moreover, the serum levels of triglyceride (TG), total cholesterol (TC), HDL-C, LDL-C and Malondialdehyde (MDA) were assessed. In diabetic rats, metformin therapy reduced serum concentration of TG (- 82.2±6 mg.dl), TC (-55.8±1 mg.dl), LDL-C (-68.46 ±7 mg.dl), MDA (-1.7±0.18 μm.L) and increased serum concentration of HDL-C (+29.1 ± 0.1 mg.dl) (significant at P ≤ 0.05). Also in diabetic rats, sitagliptin therapy reduced serum concentration of TG (-75.9±5 mg.dl), TC (-50.1±9 mg.dl), LDL-C (-62.12 ± 6 mg.dl), MDA (-1.5 ± 0.07 μm.L) and increased serum concentration of HDL-C (+27.2 ± 0.7 mg.dl) (significant at P ≤ 0.05). As the results show, about the parameters studied in this experiment, there was no significant difference between 2 groups that treated with metformin and treated with sitagliptin in the end. In other words, sitagliptin is effective on improving the lipid profile and oxidative stress like metformin. Findings of this study showed that sitagliptin is an efficient pharmaceutical composition with beneficial antidiabetic effects. However, since the effect of this drug is dependent on secretion of endogenous GLP-1, it should be used only for patients with some extent of active β-cells.
- Publication
International Journal of Pharmaceutical Research & Allied Sciences, 2016, Vol 5, Issue 2, p227
- ISSN
2277-3657
- Publication type
Academic Journal